Cybin to Host Virtual R&D Day on February 28, 2023
Cybin, a biopharmaceutical company focused on developing psychedelic therapies, will host a virtual R&D Day on February 28, 2023, from 10:00 a.m. ET to 11:30 a.m. ET. The event will showcase updates on Cybin's development pipeline, including interim results from the Phase 1/2a study of CYB003, targeted for treating major depressive disorder, and updates from the Phase 1 exploratory trial of CYB004 for generalized anxiety disorder. A Q&A session for investors will follow the presentation, and an archived webcast will be available afterward.
- None.
- None.
The event, which will be hosted by Cybin’s leadership team, will provide a progress update on the Company’s development pipeline of differentiated psychedelic-based therapeutics, including CYB003 and CYB004. Specifically, the Company plans to provide an interim readout from the ongoing Phase 1/2a study evaluating CYB003, an update from the ongoing Phase 1 exploratory CYB004-E trial evaluating IV N,N-dimethyltryptamine and a review of its clinical development program evaluating CYB004.
To participate in the event, please click here to register and access the live webcast. A Q&A session for the investment community will follow the prepared remarks. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page following the event.
About
Cautionary Notes and Forward-Looking Statements
Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybin’s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. Forward looking statements in this news release include statements regarding the Company’s plan to provide a progress update on the Company’s development pipeline, an interim readout from its Phase 1/2a study evaluating CYB003, an update on its Phase 1 exploratory CYB004-E trial, and a review of its clinical development program evaluating CYB004. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in the Company's management's discussion and analysis for the three and six month periods ended
Neither the
View source version on businesswire.com: https://www.businesswire.com/news/home/20230126005396/en/
Investors & Media:
Vice President, Investor Relations
irteam@cybin.com - or - media@cybin.com
Chief Legal Officer
1-866-292-4601
Source:
FAQ
What is the date and time of Cybin's R&D Day?
What updates will Cybin present on February 28, 2023?
How can I participate in Cybin's virtual R&D Day?
What are the targets of Cybin's CYB003 and CYB004 therapies?